Efficacy of Leuprolide Acetate 1-Month Depot for Central Precocious Puberty (CPP): Growth Outcomes During a Prospective, Longitudinal Study

Overview

Journal Int J Pediatr Endocrinol

Publisher Biomed Central

Specialty Pediatrics

Date 2011 Aug 24

PMID 21860633

Citations 21

Authors

Peter A Lee

E Kirk Neely

John Fuqua

Di Yang

Lois M Larsen

Cynthia Mattia-Goldberg

Kristof Chwalisz

Affiliations

Soon will be listed here.

Abstract

Introduction: Gonadotropin-releasing hormone analogs (GnRHa) are the treatment of choice for CPP. We investigated growth in GnRHa-naïve subjects, treated with leuprolide acetate 1-month depot for CPP.

Methods: This prospective, open-label study had a long-term, observational, follow-up period. Forty-nine females and 6 males were enrolled. Leuprolide acetate depot was administered intramuscularly every 28 days. Height and growth rate during and after treatment until adulthood were measured.

Results: Among 30 of 49 females having an adult height (AH) measurement, 29 had target heights available (mean = 163.8 cm) and 27 had pretreatment predicted adult heights (PAHs; mean = 157.4 cm). After treatment, the mean AH at mean age 21.8 years [range 13.7-26.7 years] was 162.5 cm, a mean height gain over baseline PAH of 4.0 cm. The mean height standard deviation score was -0.1 at AH.

Conclusions: Treatment of CPP with leuprolide acetate 1-month depot had beneficial effects on growth rate and preservation of AH.

Trial Registration: ClinicalTrials.gov: NCT00660010.

Citing Articles

Clinical development of the GnRH agonist leuprolide acetate depot.

Chwalisz K F S Rep. 2023; 4(2 Suppl):33-39.

PMID: 37223757 PMC: 10201295. DOI: 10.1016/j.xfre.2022.11.011.

Comparison of the effect of gonadotropin-releasing hormone agonist dosage in girls with central precocious puberty.

Jang S, Kim S, Lee M, Lee H, Kwon A, Suh J Ann Pediatr Endocrinol Metab. 2023; 28(4):283-288.

PMID: 36758971 PMC: 10765025. DOI: 10.6065/apem.2244210.105.

Final adult height in children with central precocious puberty - a retrospective study.

Knific T, Lazarevic M, Zibert J, Obolnar N, Aleksovska N, Suput Omladic J Front Endocrinol (Lausanne). 2022; 13:1008474.

PMID: 36531464 PMC: 9757689. DOI: 10.3389/fendo.2022.1008474.

Gonadotropin-releasing hormone analog therapies for children with central precocious puberty in the United States.

Popovic J, Geffner M, Rogol A, Silverman L, Kaplowitz P, Mauras N Front Pediatr. 2022; 10:968485.

PMID: 36268040 PMC: 9577333. DOI: 10.3389/fped.2022.968485.

EFFECTS OF THE GONADOTROPIN-RELEASING HORMONE AGONIST THERAPY ON GROWTH AND BODY MASS INDEX IN GIRLS WITH IDIOPATHIC CENTRAL PRECOCIOUS PUBERTY.

Donbaloglu Z, Bedel A, Cetiner E, Singin B, Behram B, Tuhan H Acta Endocrinol (Buchar). 2022; 18(2):181-186.

PMID: 36212259 PMC: 9512371. DOI: 10.4183/aeb.2022.181.

References

Brito V, Latronico A, Cukier P, Gurgel Teles M, Silveira L, Arnhold I . Factors determining normal adult height in girls with gonadotropin-dependent precocious puberty treated with depot gonadotropin-releasing hormone analogs. J Clin Endocrinol Metab. 2008; 93(7):2662-9. DOI: 10.1210/jc.2007-2183. View

Lazar L, Padoa A, Phillip M . Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity. J Clin Endocrinol Metab. 2007; 92(9):3483-9. DOI: 10.1210/jc.2007-0321. View

CLEMONS R, KAPPY M, Stuart T, Perelman A, Hoekstra F . Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty. Am J Dis Child. 1993; 147(6):653-7. DOI: 10.1001/archpedi.1993.02160300059023. View

Parker K, Lee P . Depot leuprolide acetate for treatment of precocious puberty. J Clin Endocrinol Metab. 1989; 69(3):689-91. DOI: 10.1210/jcem-69-3-689. View

Badaru A, Wilson D, Bachrach L, Fechner P, Gandrud L, Durham E . Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty. J Clin Endocrinol Metab. 2006; 91(5):1862-7. DOI: 10.1210/jc.2005-1500. View

Mul D, Oostdijk W, Otten B, Rouwe C, Jansen M, Delemarre-van de Waal H . Final height after gonadotrophin releasing hormone agonist treatment for central precocious puberty: the Dutch experience. J Pediatr Endocrinol Metab. 2000; 13 Suppl 1:765-72. DOI: 10.1515/jpem.2000.13.s1.765. View

KAULI R, Galatzer A, Kornreich L, Lazar L, Pertzelan A, Laron Z . Final height of girls with central precocious puberty, untreated versus treated with cyproterone acetate or GnRH analogue. A comparative study with re-evaluation of predictions by the Bayley-Pinneau method. Horm Res. 1997; 47(2):54-61. DOI: 10.1159/000185432. View

Neely E, Hintz R, Parker B, Bachrach L, Cohen P, Olney R . Two-year results of treatment with depot leuprolide acetate for central precocious puberty. J Pediatr. 1992; 121(4):634-40. DOI: 10.1016/s0022-3476(05)81162-x. View

Pasquino A, Pucarelli I, Accardo F, Demiraj V, Segni M, Di Nardo R . Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function. J Clin Endocrinol Metab. 2007; 93(1):190-5. DOI: 10.1210/jc.2007-1216. View

10.

Magiakou M, Manousaki D, Papadaki M, Hadjidakis D, Levidou G, Vakaki M . The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study. J Clin Endocrinol Metab. 2009; 95(1):109-17. DOI: 10.1210/jc.2009-0793. View

11.

Brauner R, Adan L, Malandry F, Zantleifer D . Adult height in girls with idiopathic true precocious puberty. J Clin Endocrinol Metab. 1994; 79(2):415-20. DOI: 10.1210/jcem.79.2.8045957. View

12.

Carel J, Eugster E, Rogol A, Ghizzoni L, Palmert M, Antoniazzi F . Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009; 123(4):e752-62. DOI: 10.1542/peds.2008-1783. View

13.

Lanes R, Soros A, Jakubowicz S . Accelerated versus slowly progressive forms of puberty in girls with precocious and early puberty. Gonadotropin suppressive effect and final height obtained with two different analogs. J Pediatr Endocrinol Metab. 2004; 17(5):759-66. DOI: 10.1515/jpem.2004.17.5.759. View

14.

Arrigo T, Cisternino M, Galluzzi F, Bertelloni S, Pasquino A, Antoniazzi F . Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty. Eur J Endocrinol. 1999; 141(2):140-4. DOI: 10.1530/eje.0.1410140. View

15.

Chumela W, Roche A, Thissen D . The FELS method of assessing the skeletal maturity of the hand-wrist. Am J Hum Biol. 2017; 1(2):175-183. DOI: 10.1002/ajhb.1310010206. View

16.

Tanaka T, Niimi H, Matsuo N, Fujieda K, Tachibana K, Ohyama K . Results of long-term follow-up after treatment of central precocious puberty with leuprorelin acetate: evaluation of effectiveness of treatment and recovery of gonadal function. The TAP-144-SR Japanese Study Group on Central Precocious Puberty. J Clin Endocrinol Metab. 2004; 90(3):1371-6. DOI: 10.1210/jc.2004-1863. View

17.

Carel J, Roger M, Ispas S, Tondu F, Lahlou N, Blumberg J . Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty. J Clin Endocrinol Metab. 1999; 84(6):1973-8. DOI: 10.1210/jcem.84.6.5647. View

18.

Eugster E, Clarke W, Kletter G, Lee P, Neely E, Reiter E . Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial. J Clin Endocrinol Metab. 2007; 92(5):1697-704. DOI: 10.1210/jc.2006-2479. View

19.

Bayley N, PINNEAU S . Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr. 1952; 40(4):423-41. DOI: 10.1016/s0022-3476(52)80205-7. View

20.

Neely E, Lee P, Bloch C, Larsen L, Yang D, Mattia-Goldberg C . Leuprolide acetate 1-month depot for central precocious puberty: hormonal suppression and recovery. Int J Pediatr Endocrinol. 2011; 2010:398639. PMC: 3062984. DOI: 10.1155/2010/398639. View